John H. Leaman's most recent trade in Traws Pharma Inc. was a trade of 16,234 Stock Option (right to purchase) done . Disclosure was reported to the exchange on Dec. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Traws Pharma Inc | John H. Leaman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 16,234 | 16,234 | - | - | Stock Option (right to purchase) | |
| Traws Pharma Inc | John H. Leaman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 4,058 | 4,058 (0%) | 0% | 0 | Common Stock | |
| Traws Pharma Inc | John H. Leaman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2025 | 12,770 | 12,770 | - | - | Stock Option (right to purchase) | |
| Traws Pharma Inc | John H. Leaman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 15,609 | 15,609 | - | - | Stock Option (right to purchase) | |
| Impel Pharmaceuticals Inc | John H. Leaman | Chief Fin. & Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Impel Pharmaceuticals Inc | John H. Leaman | Chief Fin. & Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 10,571 | 0 | - | - | Restricted Stock Units (RSUs) | |
| Impel Pharmaceuticals Inc | John H. Leaman | Chief Fin. & Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2022 | 10,571 | 10,571 | - | 0 | Common Stock | |
| Impel Pharmaceuticals Inc | John H. Leaman | Chief Fin. & Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.75 per share. | 31 Dec 2022 | 3,627 | 6,944 | - | 3.7 | 13,601 | Common Stock |
| Impel Pharmaceuticals Inc | John H. Leaman | Chief Fin. & Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Impel Pharmaceuticals Inc | John H. Leaman | Chief Fin. & Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Oct 2021 | 10,571 | 10,571 | - | - | Restricted Stock Units (RSUs) | |
| Impel Pharmaceuticals Inc | John H. Leaman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) |